Characterization of Acinetobacter clinical isolates by Yuji NAKADA et al.
 AINO  JOURNAL,  Vol.  10,  2011,  pp.  23  -26
Short report
 Characterization of Acinetobacter clinical isolates
 Yuji  NAKADA
Shiho SHIRAKI
Hiroyuki  ITAGAKI
Tomoko NAKADA
Professor,
tation,
Department  of  Nursing, Faculty
 Aino University
Undergraduate student,
and Rehabilitation
of Nursing and  Rehabili-
Department of  Nursing,
, Aino University
Medical technologist,
Part-time lecturer,
Aino Hospital
 Aino Gakuin College
 Faculty of  Nursing
Abstract
Members of the genus Acinetobacter are typical opportunistic bacterial pathogens that can 
survive for a long term even on inanimate surfaces. Acinetobacter species have natural and 
acquired antibiotic resistance mechanisms that provide resistance against a broad range of 
antimicrobial agents. Between April 2010 and March 2011, 6 clinical Acinetobacter sp. 
strains were isolated from expectoration or aspiration sputum samples in a local medical 
treatment-type hospital in Osaka prefecture. The antibiotic susceptibility breakpoint est 
showed that all the 6 isolates were ciprofloxacin-resistant. Strain AHU-70, which was 
identified as A. baumannii by  16S rRNA sequencing and polymerase chain reaction 
detection of the  blaOXA-51-like gene, showed high levels of resistance to ciprofloxacin by the 
minimum inhibitory concentration (MIC) test. Preliminary research in Japan, based on 
nationwide susceptibility surveillance of ciprofloxacin against A. baumannii isolates 
showed that approximately 90% of the isolates were ciprofloxacin-susceptible. Given these 
results, further strain level identification of isolates is required to determine whether 
resistance to ciprofloxacin is an overall trait of these bacteria in the sampled local area or is 
restricted to a specific strain within particular hospitals.
 INTRODUCTION
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 Acinetobacter species constitute prevalent op-
portunistic human pathogens that cause acute 
pneumonia, meningitis, and septicemia in immuno-
compromised patients (Humphreys et  al., 1996). 
They are widely distributed in nature and in 
hospital environments such as intensive care 
units, due to their ability for long-term survival 
even on inanimate surfaces (Kappstein et al., 
2000). A. baumannii, A. calcoaceticus, A. haemo-
lyticus, A. johnsonii, A. junii, A.  lwoffii, A. 
 parvus,  A. radioresistens, A. schindleri, A. 
ursingii, A. genomic species  3,  13TU, 10, and 11 
have been isolated from human specimens (Dortet 
et  al., 2006). Particularly, A. baumannii is most 
frequently isolated from humans and also appears 
to be the Acinetobacter species with the greatest 
clinical importance. Identification of Acineto-
bacter species on the bases of abbreviated
susceptibility, ciprofloxacin
phenotypic tests is difficult, and genetic methods 
such as standard DNA-DNA hybridization 
(Bouvet and Grimont, 1986) and sequencing of the 
16S rRNA gene (Ibrahimet al., 1997) or the 16-23S 
rRNA intergenic spacer region (Lee et al., 2011) 
have been proposed. It is also known that 
Acinetobacter species have natural and acquired 
antibiotic resistance mechanisms that provide 
increasing resistance against a broad range of 
antimicrobial agents (Lee et  al., 2011). In Japan, 
Acinetobacter species for which minimum inhibi-
tory concentrations (MICs) of imipenem (IMP), 
amikacin (AMK), and ciprofloxacin (CPFX) are 
 16  g/mL,  > 32  g/mL, and 4  g/mL,  respec-
tively, are defined as multidrug-resistant  Acine-
tobacter species (MDRA), according to the 
Infectious Diseases Control Law in correspond-
ence to the increased hospital infection by MDRA 
(Yuji et  al., 2011).
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Bacterial isolates and growth conditions
 Between April 2010 and March 2011, clinical 
Acinetobacter sp. strains were isolated from 
expectoration or aspiration sputum samples of 
patients with different infections in a medical 
treatment-type hospital (approximately 1,000 
beds) in Osaka prefecture. Genus classification of 
the strains was performed using the MicroScan 
WalkAway Plus (Siemens, Germany) fully auto-
mated instrument. A. baumannii ATCC17978 is 
a standard strain for which the complete genomic 
sequence is available (Michael et al., 2007); this 
strain was isolated from a 4-month-old infant with 
meningitis. All the strains were cultured at 37°C 
in Mueller-Hinton (MH; Oxoid, USA) medium 
supplemented with antibiotics when appropriate.
 DNA techniques
 DNA purification and other DNA manipulations 
were conducted as previously described (Nakada 
and Itoh, 2002; Sambrook et  al., 2001). A poly-
merase chain reaction (PCR) was performed with 
KOD-plus DNA polymerase (Toyobo Biochemi-
cals, Japan) in a GeneAmp PCR System 2700 
thermal cycler (Applied Biosystems, USA) under 
the reaction conditions recommended by the 
supplier. Fragment size of the PCR products was 
determined by 1.5% agarose gel electrophoresis.
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by using a BLAST program.
Detection  of  the  blaOXA-51-like gene
 The  blaOXA-51-like gene, which appears to be 
intrinsic to A. baumannii (Woodford et  al.  , 2006), 
was detected by PCR by using the primer pair of 
OXA-51-likeF and OXA-51-likeR (Table 1). PCR 
conditions were as follows: 94°C for 3 min; 28 
cycles of 94°C for 1  min, 60°C for 1  min, and 68°C 
for 1  min; and a final extension at 68°C for 4  min.
Antibiotic susceptibility test
 Antimicrobial breakpoint ests were conducted 
by FALCO biosystems Ltd. by using the Micro-
Scan Walk Away Plus (Siemens, Germany) fully 
automated instrument. Isolates were determined 
to be susceptible  (S), intermediate (I), or resistant 
(R) according to the antibiotic breakpoint guide-
lines of the Clinical and Laboratory Standards 
Institute (CLSI) for Acinetobacter sp. (CLSI, 2006). 
 The MICs for IMP, AMK, and CPFX, which are 
used to define MDRA in Japan, were also 
determined by the standard broth dilution method 
according to the guidelines of the CLSI. Over-
night cultures of each Acinetobacter sp. strain 
were diluted in saline to an optical density of 0.1 at 
600 nm of (approximately 1  x 108 CFU/mL), and a 
portion of the adjusted cell suspension  (-105cells) 
was inoculated on the MH medium containing 
antibiotics as indicated. The cell cultures were 
then incubated overnight at  37°C  .
Nucleotide sequencing of the 16S  rRNA gene
 The  16S rRNA gene of the AUH-70 strain was 
amplified by PCR with a universal primer pair of 
UFPL and URPL (Lipuma et  al.  , 1999; Table 1). 
PCR conditions were as follows: 94°C for 3  min; 30 
cycles of 94°C for 1 min, 55°C for 1  min, and 68°C 
for 1.5  min; and a final extension at 68°C for 4  min. 
The resultant approximately  1.5-kbp fragment 
was purified using a PCR Purification Kit (WAKO, 
Japan), and its nucleotide sequence was deter-
mined using the  ABI3130 DNA sequencer and a 
Big-Dye Terminator Sequencing Kit (Applied 
Biosystems, USA). Sequence assembly was per-
formed using ATGC version 5.0 (Genetyx 
Corporation, Japan), and the resultant sequence 
was compared with those in the NCBI database
Table 1
 RESULTS
Isolated strains
 Within one year, 6 patients developed Acineto-
bacter sp. infection, and clinical isolates, including 
AUH-70 strain, were obtained from expectoration 
or aspiration sputum samples (Table 2). The 
patients included those in old-age chronic stage 
wards (A, B) and specific disease wards (C).
Identification of the AUH-70 strain
 The 16S rRNA genomic region containing 
approximately 1500 nucleotides was amplified 
(Fig. 1), and 1406  bp sequence data were obtained 
by direct sequencing. Alignment and comparison
 PCR primers and their target genes and amplicon sizes
Primer Oligonucleotide sequence  (5' -3'  ) Target Amplicon size (bp)
UFPL
URPL
OXA-51-likeF
OXA-51-likeR
AGTTTGATCCTGGCTCAG
GGTTACCTTGTTACGACTT
TAATGCTTTGATCGGCCTTG
TGGATTGCACTTCATCTTGG
16SrRNA
gene
 blaOXA-51-like
1492*
353
*Corresponding to positions 9-1500 in the Escherichia  coli numbering system
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Table 2 Specimens
Characterization of Acinetobacter clinical isolates
and antimicrbial breakpoints   of Acinetobactersp. isolates
 bp
Isolate code Hospital Breakpoint
(Strain) ward
Specimens
 PIPC CAZ  IPM  MINO AMK CPFX
E41 A aspiration sputum R S S      S S R
N21 B expectoration S S S      S S R
C41 C aspiration sputum R S S      S S R
C42 C aspiration sputum R S S      S S R
N22 (AUH-70) B aspiration sputum S S S      S S R
C43 C aspiration sputum S S S      S S R
A and B: old-age chronic stage wards, C:
PIPC: piperacillin, CAZ:  ceftazidime,  IPM:
CPFX: ciprofloxacin.
specific disease wards.
 imipenem, MINO: minocycline,  AMK:
Table 3
 amikacin,
1500
500
400
300
200
100
M 1 2
MICs  of  A.  baumannii ATCC17978 and the AUH-70
strain
Lane 1: 16S  rRNA gene, lane 2:  bla0XA-51-like g ne, M: 100-bp DNA 
marker 
Fig. 1 PCR results of amplified fragments of the 16S rRNA 
      gene and  bla0XA-51-like gene from the AUH-70 strain
of this region with the A. baumannii ATCC17978 
16S rRNA gene which is positioned from nt 53 to 
nt 1458 (Michael et al., 2007), indicated complete 
homology. Moreover, sequence similarity with 
the equivalent 16S rRNA gene region of A. 
 baumannii  UMB001, A. baumannii ABNIH1, A. 
baumannii  ATCC19606, and A. baumannii AYE 
was greater than 99.9%. Furthermore, PCR 
detection of the  bla0XA-51-like gene, which appears 
to be intrinsic to A. baumannii, was positive (Fig. 
1). These results suggest that the AUH-70 strain 
was A.  baumannii.
Antibiotic susceptibility
 The antimicrobial breakpoint test showed that 
all 6 isolates were CPFX-resistant; moreover, of 
these 6 isolates, 3 were piperacillin-resistant 
(Table 2). Furthermore, the resultant of MIC test 
showed that the AUH-70 strain was highly 
resistant to CPFX (Table 3). On the other hand, 
IMP and AMK was still effective to the clinically
Strain
MICs  (ug/mL)
Imipenem  Amikacin Ciprofloxacin
 A.
A.
??
?
?
?
0.25
0.25
0.5
0.5
0.125
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isolated AUH-70 strain, as was
 ATCC17978 standard strain.
DISCUSSION
A.  baumannii
 In this study, we examined the antibiotic 
susceptibility of Acinetobacter sp. isolates  ob-
tained from a medical treatment-type hospital in 
Osaka prefecture. Within one year, 6 patients 
developed Acinetobacter sp. infection, and all 
isolates obtained from these patients showed 
CPFX resistance. CPFX is a fluoroquinolone-
type antibiotic that exerts its antibacterial effects 
by inhibiting DNA gyrase and topoisomerase IV 
enzymes, which are necessary for separating 
bacterial DNA, thereby inhibiting cell division. 
Nationwide susceptibility surveillance studies of 
CPFX against A. baumannii isolated from pa-
tients between 2001 and 2005 (Yamaguchi et al, 
2008) and between 2006 and 2010 (http: //www. 
kansensho. or. jp/mrsa/index. html) showed that 
approximately 90% of the collected isolates were 
susceptible to this antibiotic. These results 
suggest 2 possibilities. One is the rapid evolution 
of the CPFX-resistant Acinetobacter sp. in the 
sampled local area, and the other is the develop-
ment of a few CPFX-resistant strains in a 
particular hospital. In the current study, the 
number of affected patients in specific wards, and 
the limited variation in antibiotic susceptibility 
patterns, seem to support the likelihood of 
expansion of a few resistant strains in the hospital; 
however there is no conclusive evidence for this
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hypothesis. From the standpoint of nosocomial 
infection control, a surveillance study involving 
strain identification by REP-PCR, VNTR, or PFGE 
(Pourcel et al, 2011) is required.
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